Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Immunohistopathologically documented relapsed or refractory CD20+ indolent lymphomas or mantle cell lymphoma~  * Indolent B-cell lymphomas including any of the following subtypes:~    * Follicular lymphoma (grade I, II, or III)~   * Small lymphocytic lymphoma or chronic lymphocytic leukemia~   * Marginal zone lymphoma (splenic, nodal, and extra-nodal)~   * Lymphoplasmacytoid lymphoma~* Ineligible for or unwilling to participate in other FHCRC/UWMC protocols~* Serological evidence of prior exposure to Epstein-Barr virus~* Must agree to undergo peripheral blood drawing, bone marrow biopsy, lymph node biopsy, and nuclear medicine imaging~* Must agree to cytoreductive chemotherapy if necessary to reduce lymph nodes to \< 5 cm in diameter or circulating B lymphocyte counts to \< 5,000/mm\^3~* No pulmonary involvement~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* Not specified~Life expectancy:~* At least 90 days~Hematopoietic:~* Not specified~Hepatic:~* No active hepatitis B infection~Renal:~* Not specified~Other:~* No HIV positivity~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of hypersensitivity reactions to murine proteins~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 months since prior rituximab, tositumomab, or ibritumomab~* No prior allogeneic stem cell transplantation~* No other concurrent immunotherapy (e.g., interferons, vaccines, or other cellular products)~Chemotherapy:~* At least 2 years since prior fludarabine or cladribine~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* No concurrent systemic corticosteroids except to treat toxicity from chemotherapy or cellular immunotherapy~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* At least 4 weeks since prior immunosuppressive therapy and recovered~* No concurrent pentoxifylline~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).